CYP3A5*3 polymorphism

Intended Use: To assess genetic risk of abnormal drug metabolism for CYP3A4 and/or CYP3A5*3 substrates. May aid in drug selection and dose planning for drugs metabolized by CYP3A4 and/or CYP3A5*3.

Specimen Required: Lavender (EDTA), Pink (K2EDTA)

Patient Preparation 

• Sample Collection: 2 Tubes / EDTA Blood / 2 mL per tube
• Specimen Preparation: Do not freeze. Transport 3 mL whole blood. (Min: 1 mL)
• Storage/Transport Temperature: Refrigerated
• Unacceptable Conditions
  • Plasma or serum.
  • Heparinized specimens.
  • Frozen specimens in glass collection tubes.

• Remarks: Counselling and informed consent are recommended for genetic testing.
• Stability: Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month

Methodology: This assay is a real-time PCR assay for the qualitative detection and allelic discrimination of the G 6986 A (rs776746) single nucleotide polymorphism.

Sample Received to Report Turnaround Time (TAT): Twice in a week (Scheduled test)

Reference Interval: –

Interpretive Data: Refer to report